Skip to Main Content

Dronabinol for Pain and Inflammation in Adults Living with Sickle Cell Disease

Conditions

Other Hematopoietic | Sickle Cell Disorders

Phase Pilot

What is the purpose of this trial?

This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).

  • Trial with
    Yale Cancer Center
  • Start Date
    07/02/2019
  • End Date
    06/30/2020
Trial Image

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/06/2019
  • Study HIC
    #2000021179